Comparative Pharmacology
Head-to-head clinical analysis: SULLA versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULLA versus SULSOXIN.
SULLA vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
100 mg orally once daily, increased to 200 mg daily if needed.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 30 hours)
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic